Navigation Links


Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Computer Electronics, Biotechnology, Clinical Trials & Medical Discoveries Click to view news release full screen  



Combination of Toraymyxin™ and EAA™ represents first theranostic trial in sepsis

TORONTO, Oct. 19 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI), a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, today announced initiation of its U.S. pivotal trial of Toraymyxin™, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis. The Cooper Health System, in Camden, New Jersey, which also acts as the coordinating centre for the EUPHRATES trial, has been screening patients using the FDA approved protocol for inclusion and exclusion criteria. After determining the suitability of the protocol, patients have now been enrolled in the trial.

The EUPHRATES (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock) trial is a randomized, double-blinded control trial of standard of care versus standard of care and Toraymyxin™ directed by Spectral's Endotoxin Activity Assay (EAA™), an FDA cleared assay for use in sepsis. This is the first theranostics trial, a combination therapeutic and diagnostic, in the area of sepsis.

"The initiation of our EUPHRATES trial is a major milestone for the Company. This is a step closer to providing U.S. patients the opportunity to access this unique therapeutic device," said Dr. Paul Walker, President and CEO of Spectral. "In part due to the few therapeutic options available to treat the more than 250,000 patients diagnosed with severe sepsis in the U.S. each year, this disease remains a leading cause of mortality. Toraymyxin™ has been used safely on more than 70,000 patients worldwide and, when guided by our EAA™ diagnostic, has the potential to address this large unmet medical need. We are now qualifying additional sites and, following the upcoming investigators meeting, anticipate that all 15 sites should be active within the next three months."

The EUPHRATES trial is expected to enroll approximately 360 patients at 15 sites throughout the U.S. and will have a primary end point of 28 day mortality. About Spectral Diagnostics Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment for severe sepsis and septic shock. Toraymyxin™ is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the detection of endotoxin. Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Toraymyxin™ has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively in more than 70,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin™. More than 250,000 patients are diagnosed with severe sepsis and septic shock in the U.S. each year, representing a greater than $1 billion market opportunity for Spectral.

Spectral is listed on the Toronto Stock Exchange under the symbol SDI. Forward-looking statement Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws.  Implicit in this information, particularly in respect of our future operating results and economic performance and anticipated events or results, are assumptions based on beliefs of our senior management as well as information currently available to it.  These assumptions, although considered reasonable by us at the time of preparation, may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, our ability to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.  For more exhaustive information on these risks and uncertainties you should refer to our most recently filed annual information form which is available at  Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

SOURCE Spectral Diagnostics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral to bring anti-sepsis therapy to the U.S. market
2. Spectral announces third quarter 2008 results
3. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
4. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
5. Spectral announces 2008 financial results
6. Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
7. Spectral announces first quarter 2009 results
8. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
9. Spectral announces second quarter 2009 results
10. Spectral appoints new board member
11. First Spaceborne Hyperspectral Imager Will Use QImaging Rolera-MGi EMCCD Camera
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
(Date:10/29/2015)... Minn. , Oct. 29, 2015   MedNet ... supports the entire spectrum of clinical research, is pleased ... Minnesota High Tech Association (MHTA) as one of only ... in the "Software – Small and Growing" category. The Tekne ... individuals who have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):